RACHAEL STILLWAGON: Open Payments
NPI 1437174208 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,586 in 122 payments from 19 companies in 2025. Trend: 2023 $949 · 2024 $1,245 · 2025 $2,586
Food & beverage: $2,463Education: $117Consulting: $6
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 15 | $547 |
| GlaxoSmithKline, LLC. | 34 | $432 |
| CSL Behring | 15 | $399 |
| AstraZeneca Pharmaceuticals LP | 6 | $346 |
| Novartis Pharmaceuticals Corporation | 12 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $177 |
| Amgen Inc. | 5 | $101 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| Pharming Healthcare, Inc. | 2 | $61 |
| GC Biopharma USA, Inc. | 3 | $49 |
Products named: DUPIXENT, NUCALA, Andembry, TEZSPIRE, FASENRA, CUVITRU, Hizentra, TRELEGY ELLIPTA.
Industry payments across AZ — which companies pay providers there.
